ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD

Board Appoints Officers 

ALLEN, Texas, March 25, 2024 /PRNewswire/ -- Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") On March 19th, 2024, a Special Meeting of the Shareholders of ENZC  of which a quorum was present representing over 51% of the voting right of the company was held and new board of directors was elected.

This new board consists of Harry Zhabilov, Chairman of the Board; Dr. Lachezar Ivanov, and Dr. Gaurav Chandra. Dr. Ivanov and Harry Zhabilov have accepted their position as director, as of this date, Dr. Chandra has not.  Immediately following this Special Shareholder Meeting,  the New Board of Directors were noticed by Harry Zhabilov of a Special Called Meeting of the Board of Directors, which was held March 21, 2024 and a quorum was present.  The new officers of the corporation were elected.

The new executive officers appointed by the Board of Directors are Steven Sharabura – Chief Executive Officer, Diana Zhabilov – Chief Financial Officer, and Harry Zhabilov – Chief Science Officer. Dr Gaurav Chandra was duly noticed and nominated as an officer but declined the position of CEO.  Dr. Chandra remains a director of the Company.

Steve Sharabura stated, "I am working with the board to formulate a new business strategy and identify acquisition targets. The Company will release additional information on our progress in the coming weeks."

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.

While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to identify acquisition targets and formulate a business strategy for implementation. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.

SOURCE Enzolytics, Inc.